

Theme	Session Title	Presentation No.	Abstract No.	Lecture title	Speaker	Country
Tumor-type specific Sessions	DIPG (basic)	DIPB-IS-01	IS-20	Molecular pathways and therapeutic opportunities in DIPG	Nada Jabado	Canada
		DIPB-O-02	DIPG-05	Histone H3.3 K27M impairs Ser31 phosphorylation, resulting in chromosomal instability, loss of cell cycle checkpoint control, and tumor formation	Charles Day	USA
		DIPB-O-03	DIPG-03	Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma	Rintaro Hashizume	USA
		DIPB-P-04	DIPG-13	Targeting hypoxia and mitochondria with repurposed metabolic drugs as an approach to radiosensitization for Diffuse Intrinsic Pontine Gliomas (DIPG)	Han Shen	Australia
		DIPB-P-05	DIPG-22	Dissecting the oncogenic role of FOXR2 in diffuse intrinsic pontine glioma	Jessica Tsai	USA
		DIPB-P-06	DIPG-27	Targeting Facilitates Chromatin Transcription (FACT) as a novel strategy for Diffuse Intrinsic Pontine Glioma (DIPG) that enhances response to histone deacetylase (HDAC) inhibition	Maria Tsoli	Australia
		DIPB-P-07	DIPG-31	Molecular mechanisms and functional impact of aberrant splicing in diffuse midline gliomas	Ammar Naqvi	USA
		DIPB-P-08	DIPG-63	Loss of the H4 lysine methyltransferase KMT5B drives invasion / migration by depleting H3K27me3 at loci otherwise retained in H3K27M mutant DIPG cells	Ketty Kessler	UK
		DIPB-P-09	DIPG-73	Senescence associated secretory phenotype as a mechanism of resistance and therapeutic vulnerability in BMI1 inhibitor treated DIPG	Sujatha Venkataraman	USA
		DIPB-P-10	DIPG-58	Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum of diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation	David Castel	France
		DIPB-P-11	DIPG-14	Targeting Polo-Like Kinase 1 in combination with key oncogenic drivers in DIPG: from single agent to combination strategies.	Benjamin Rayner	Australia
		DIPB-P-12	DIPG-15	Polyamine pathway inhibition is a potent novel therapeutic strategy against Diffuse Intrinsic Pontine Glioma	Maria Tsoli	Australia
		DIPB-P-13	DIPG-16	Combination of arginine depletion and polyamine inhibition as an anticancer strategy for diffuse intrinsic pontine glioma (DIPG)	Aaminah Khan	Australia
		DIPB-P-14	DIPG-21	Induction of mitotic abnormalities and BMI-1 modulation to treat diffuse intrinsic pontine glioma	Rachid Drissi	USA
		DIPB-P-15	DIPG-53	Characterizing the role of PPM1D mutations in the pathogenesis of Diffuse Intrinsic Pontine Gliomas (DIPGs)	Prasidda Khadka	USA
		DIPB-P-16	DIPG-29	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (PI3K) inhibition drives Protein Kinase C Activation (PKC) in Diffuse Intrinsic Pontine Glioma (DIPG)	Ryan Duchatel	Australia
		DIPB-P-17	DIPG-51	ACVR1 mutations promote tumor growth in models of diffuse intrinsic pontine glioma	Jennifer Ocasio Adorno	USA
		DIPB-P-18	DIPG-62	Preclinical evaluation of imipridone-based combination therapies in pediatric H3K27M mutant diffuse intrinsic pontine glioma (DIPG)	Robyn Borsuk	USA
		DIPB-P-20	DIPG-43	Can we reprogram diffuse intrinsic pontine glioma (DIPG)? Exploring the role of distalless/Dlx homeobox gene regulation of oligodendroglial progenitor cells (OPC) in the developing vertebrate nervous system	David Eisenstat	USA
		DIPB-P-21	DIPG-54	A non-invasive prognostic circulating miRNAs signature in diffuse intrinsic pontine gliomas	Loris De Cecco	Italy
		DIPB-P-22	DIPG-59	Upregulation of prenatal pontine ID1 signaling in DIPG	Micah Harris	USA
		DIPB-P-23	DIPG-70	Disordered DNA methylation in DIPG underlies phenotypic plasticity	Michael Koldobskiy	USA
		DIPB-P-24	DIPG-76	Histone H3 phosphorylation in H3K27M midline gliomas	Liang Zhang	USA
		DIPB-P-25	DIPG-78	Revertance of the H3K27M mutation rescues chromatin marks necessary for oncogenesis in diffuse midline glioma	Cody Nesvick	USA
		DIPB-P-26	DIPG-79	H3K27M induces epigenetic and oncogenic changes that are partially reversed by small molecule Aurora kinase B/C inhibition	Adam Green	USA
		DIPB-P-27	DIPG-07	High throughput drug screening identifies potential new therapies for Diffuse Intrinsic Pontine Gliomas (DIPGs)	Dannielle Upton	Australia
		DIPB-P-28	DIPG-18	Identification of targetable pathway dependencies in Diffuse Intrinsic Pontine Glioma.	Sarah Parackal	Canada
		DIPB-P-29	DIPG-32	Akt signaling drives resistance to ONC201 in Diffuse Intrinsic Pontine Glioma (DIPG)	Evangeline Jackson	Australia
		DIPB-P-30	DIPG-34	Super elongation complex as a targetable dependency in H3K27M+ diffuse midline glioma	Nathan Dahl	USA
		DIPB-P-31	DIPG-44	A gain of function Ezh2 mutation delays Diffuse Intrinsic Pontine Glioma progression	Swati Dhar	USA
		DIPB-P-32	DIPG-47	Histone mutations enhance RAS mediated ERK5 growth signaling in diffuse midline gliomas	Sameer Agnihotri	USA
		DIPB-P-33	DIPG-60	Pilot study of circulating tumor cells in pediatric high grade brain tumors	Dristhi Ragoonanan	USA
		DIPB-P-34	DIPG-08	Electronic sequencing provides optimized quantification of serial, multi-gene molecular response in the CSF of children with high-grade glioma	Andrea Franson	USA
		DIPB-P-35	DIPG-12	Targeting epigenetic modifiers to induce immune signaling in DIPG	Ashley Tetens	USA
		DIPB-P-36	DIPG-39	Novel proteomic analysis reveals epigenetic therapeutic targets in pediatric glioma	Amanda Saratsis	USA
		DIPB-P-37	DIPG-40	Targeting master regulator dependencies in diffuse intrinsic pontine glioma (DIPG)	Jovana Pavisic	USA
		DIPB-P-38	DIPG-41	Dissecting the mechanistic basis for ACVR1 and PIK3CA mutation co-occurrence in diffuse midline gliomas using genetically engineered mouse models	Jerome Fortin	Canada
		DIPB-P-39	DIPG-57	Transcriptomic and proteomic analyses of DIPG response to ONC201	Sreepadha Sridharan	USA
		DIPB-P-40	DIPG-68	Alpha-thalassemia X-linked mental retardation protein (ATRX) loss-of-function in a mouse model of diffuse intrinsic pontine glioma	Chen Shen	USA
		DIPB-P-41	DIPG-71	Selective HDAC inhibitor RG2833 induces DIPG cell death via downregulation of the NFkB pathway	Katherine Barnett	USA
		DIPB-P-42	DIPG-83	Using copper chelating agents to target receptor tyrosine kinase signalling in diffuse intrinsic pontine glioma (DIPG)	Filip Michniewicz	Australia
		DIPB-P-43	DIPG-50	A novel patient-derived mouse model of radiation-associated diffuse midline glioma following medulloblastoma	Jacqueline Whitehouse	Australia
		DIPB-P-44	DIPG-10	Optimal HDAC inhibition in diffuse intrinsic pontine glioma	Nicholas Vitanza	USA
		DIPB-P-45	DIPG-56	Exploration of tumor/stroma interactions in DIPG xenograft by species-specific RNA-seq deconvolution indicates a role of microglia cell in DIPG development	Marie-Anne Debily	France
		DIPB-P-46	DIPG-19	Targeting ATM mutation in metastatic diffuse midline glioma – a case of sustained response using PARP inhibitor	Karen Tsui	New Zealand